Fetal hemoglobin level and nutritional status in patients with sickle cell disease

Sherif M. Badawy*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients' nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age.

Original languageEnglish (US)
Article number63
JournalNutrition Journal
Volume15
Issue number1
DOIs
StatePublished - Jul 8 2016

Fingerprint

Fetal Hemoglobin
Hydroxyurea
Sickle Cell Anemia
Nutritional Status
National Institutes of Health (U.S.)
United States Food and Drug Administration
Cost-Benefit Analysis
Guidelines
Growth

Keywords

  • Fetal hemoglobin
  • Hydroxyurea
  • Nutrition
  • Sickle cell disease

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

@article{b3f06cb1f7b2433684e31a535384ce5b,
title = "Fetal hemoglobin level and nutritional status in patients with sickle cell disease",
abstract = "Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients' nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age.",
keywords = "Fetal hemoglobin, Hydroxyurea, Nutrition, Sickle cell disease",
author = "Badawy, {Sherif M.}",
year = "2016",
month = "7",
day = "8",
doi = "10.1186/s12937-016-0181-x",
language = "English (US)",
volume = "15",
journal = "Nutrition Journal",
issn = "1475-2891",
publisher = "BioMed Central",
number = "1",

}

Fetal hemoglobin level and nutritional status in patients with sickle cell disease. / Badawy, Sherif M.

In: Nutrition Journal, Vol. 15, No. 1, 63, 08.07.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fetal hemoglobin level and nutritional status in patients with sickle cell disease

AU - Badawy, Sherif M.

PY - 2016/7/8

Y1 - 2016/7/8

N2 - Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients' nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age.

AB - Hydroxyurea is the only medication approved by the U.S. Food and Drug Administration for sickle cell disease, and there is strong evidence to support the efficacy and the cost effectiveness of using hydroxyurea is patients with sickle cell disease by increasing fetal hemoglobin levels. It is important to clarify the relationship between patients' nutritional status/intake and fetal hemoglobin levels. In particular, hydroxyurea has been recommended for patients with poor growth, and the recent guidelines from the National Institute of Health suggested offering hydroxyurea to patients as young as nine month old of age.

KW - Fetal hemoglobin

KW - Hydroxyurea

KW - Nutrition

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84979673360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979673360&partnerID=8YFLogxK

U2 - 10.1186/s12937-016-0181-x

DO - 10.1186/s12937-016-0181-x

M3 - Article

C2 - 27390841

AN - SCOPUS:84979673360

VL - 15

JO - Nutrition Journal

JF - Nutrition Journal

SN - 1475-2891

IS - 1

M1 - 63

ER -